Literature DB >> 31230189

Risk factors for relapse and long-term outcome of idiopathic retroperitoneal fibrosis.

Diego Moriconi1, Domenico Giannese2, Riccardo Capecchi3, Adamasco Cupisti3, Simone Barsotti3, Riccardo Morganti4, Eugenio Orsitto5, Antonio Gaetano Tavoni3, Maria Francesca Egidi2.   

Abstract

BACKGROUND: Retroperitoneal fibrosis (RF) is a rare disease of unclear etiology characterized by the presence of fibroinflammatory tissue in the retroperitoneal space, which can entrap and obstruct retroperitoneal structures, notably the ureters. The disease responds well to steroid therapy, but tends to recur even after years. The aim of our study was to evaluate the long-term renal outcome of patients affected by idiopathic retroperitoneal fibrosis looking for predictive risk factors for recurrence of the disease and progression to end-stage renal disease.
METHODS: Retrospective observational study of patients with idiopathic RF diagnosed from 2004 to 2017 and follow-up of at least 1 year after the end of first course therapy with steroid, with or without tamoxifen (TMX) and with urological procedures when applicable.
RESULTS: Forty-three patients were included in the study. The follow-up was 93 ± 52 months. All the patients obtained remission after therapy that was maintained until the last observation in 26 of them. In 17 patients, there was at least one recurrence. Risk factors associated with relapse were identified and resulted in smoking habit, onset with acute kidney injury (AKI), low back pain and antinuclear antibodies (ANA) positivity. Renal function remained fairly stable during the long-term follow-up. The renal end-point (doubling of serum creatinine or ESRD) occurred in 8% of the patients; however, eGFR in patients with relapse was similar to that of non-recurrent at the diagnoses, but it decreased over time more in the relapsing than in non-relapsing patients (p group = 0.20; p time = 0.001; p time × group interactions = 0.04). Based on these 4 predictor conditions, patients were divided into "low risk" (with 0-1 risk factor), and "high risk" (3-4 risk factors). The renal end-point occurred in 40% of high-risk patients, while none of the low-risk patients reached it (p = 0.02).
CONCLUSIONS: Smoking habit, AKI at diagnosis, ANA positivity and lumbar pain were associated with relapse of RF after initial remission due to steroid and/or TMX therapy; the combination of these conditions was also predictive of worse renal function outcome. Identification of risk factors for relapse can be useful not only to modulate the choice, the dosage of first-line treatment and the duration of maintenance therapy but also for preventing a progressive loss of kidney function, as well.

Entities:  

Keywords:  Kidney outcome; Predictors of relapse; Retroperitoneal fibrosis

Mesh:

Substances:

Year:  2019        PMID: 31230189     DOI: 10.1007/s10157-019-01759-w

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  4 in total

Review 1.  Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis.

Authors:  Paride Fenaroli; Federica Maritati; Augusto Vaglio
Journal:  Curr Rheumatol Rep       Date:  2021-02-10       Impact factor: 4.592

2.  Renal Involvement in IgG4-Related Disease: From Sunlight to Twilight.

Authors:  Riccardo Capecchi; Domenico Giannese; Diego Moriconi; Angelo G Bonadio; Federico Pratesi; Cristina Croia; Maria F Egidi; Ilaria Puxeddu; Antonio G Tavoni; Paola Migliorini
Journal:  Front Med (Lausanne)       Date:  2021-03-31

3.  Idiopathic retroperitoneal fibrosis mimicking infiltrative malignancy: a case report.

Authors:  Miho Akabane; Shusuke Haruta; Takeshi Fujii; Masayuki Urabe; Yu Ohkura; Masaki Ueno; Harushi Udagawa
Journal:  J Int Med Res       Date:  2022-02       Impact factor: 1.671

Review 4.  Renal Involvement in Retroperitoneal Fibrosis: Prevalence, Impact and Management Challenges.

Authors:  Ichiro Mizushima; Mitsuhiro Kawano
Journal:  Int J Nephrol Renovasc Dis       Date:  2021-07-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.